Phase 2 Trial of TGF-β Inhibition (OT-101) With Anti-PD-1 (Pembrolizumab) in Patients With Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Trabedersen (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms M201
- Sponsors Oncotelic Therapeutics
- 13 Mar 2024 Planned End Date changed from 1 Dec 2026 to 1 Dec 2029.
- 13 Mar 2024 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2028.
- 03 Jan 2023 Planned initiation date changed from 1 Dec 2022 to 1 Jun 2023.